C6 Antibody (Monoclonal) , Biotinylated

A biotin conjugated murine monoclonal antibody to an epitope on C6 protein.

Product Specifications

Citations 7
Clonality

Monoclonal
Immnogen
Applications See citations and technical data sheet for application info.
Concentration 0.2 mg/mL
Conjugate Biotin
Cross Reactivity

Human, Baboon, Cynomolgus macaque, Rhesus macaque.
Technical Documents

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog Number A706
Catalog Number (CE) N/A
Size 250 µL
Price (USD) $365.00
Price (EURO) 330,00 €
Request an Order

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

A biotin conjugated murine monoclonal antibody to an epitope on C6 protein.
Size 250 µL
Concentration

0.2 mg/mL

Applications See citations and technical data sheet for application info.
Form Liquid. Phosphate Buffered Saline (pH 7.0 ± 0.2), 1% Bovine Serum Albumin, with ≤ 0.1% Sodium Azide.
Clonality Monoclonal
Immunogen Purified human protein.
Conjugate Biotin
Cross Reactivity Human, Baboon, Cynomolgus macaque, Rhesus macaque.
Isotype IgG1k
Purity ≥ 95% by SDS PAGE
Source

Mouse
Specificity This monoclonal antibody was raised against purified human C6. It is specific for an antigen expressed both on the native C6 molecule as well as on C6 in the MAC. It will not inhibit lysis of EA and will bind to MAC bound to a membrane.
Storage

Short term (30 days) 4˚C. Long term at or below –20˚C.
Background

Complement protein, C6 is a single-chain glycoprotein with a molecular weight of 108 kD. The C6 protein is present in serum at a concentration of approximately 60 μg/ml. Upon activation of the Classical, Lectin or Alternative Complement Pathways, C6 binds to C5b and becomes integrated into the Terminal Complement Complex (TCC). The Terminal Complement Complex (TCC) is the general term for both membrane bound C5b-9 (or Membrane Attack Complex; MAC) and fluid phase SC5b-9. Assessment of the TCC is an excellent marker for qualifying the extent of Terminal Pathway activation in vivo or in vitro. TCC can be deposited on the surface of transformed cells, biomaterials, and a variety of other surfaces.

Certificate of Analysis

Showing results for
No results found for